Nuveen Asset Management LLC lessened its position in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) by 15.1% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 146,033 shares of the medical technology company’s stock after selling 26,048 shares during the quarter. Nuveen Asset Management LLC owned about 0.23% of Alphatec worth $687,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. raised its position in shares of Alphatec by 12.8% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 113,800 shares of the medical technology company’s stock valued at $535,000 after buying an additional 12,947 shares during the period. Cerity Partners LLC raised its position in shares of Alphatec by 0.8% during the 2nd quarter. Cerity Partners LLC now owns 2,418,061 shares of the medical technology company’s stock valued at $11,365,000 after buying an additional 18,086 shares during the period. Captrust Financial Advisors purchased a new stake in shares of Alphatec during the 2nd quarter valued at approximately $48,000. American International Group Inc. raised its position in shares of Alphatec by 17.7% during the 2nd quarter. American International Group Inc. now owns 27,230 shares of the medical technology company’s stock valued at $128,000 after buying an additional 4,092 shares during the period. Finally, Blair William & Co. IL purchased a new stake in shares of Alphatec during the 2nd quarter valued at approximately $94,000. 38.67% of the stock is currently owned by hedge funds and other institutional investors.

Several analysts have recently commented on the stock. BidaskClub raised shares of Alphatec from a “hold” rating to a “buy” rating in a research report on Tuesday, September 29th. Cowen initiated coverage on shares of Alphatec in a report on Thursday, September 3rd. They issued an “outperform” rating and a $12.00 target price for the company. Lake Street Capital lifted their target price on shares of Alphatec from $13.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, October 8th. Canaccord Genuity lifted their target price on shares of Alphatec from $9.00 to $12.00 and gave the company a “buy” rating in a report on Thursday, October 8th. Finally, HC Wainwright lifted their target price on shares of Alphatec from $9.00 to $12.00 and gave the company a “buy” rating in a report on Monday, October 12th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $10.64.

In other news, CFO Jeffrey G. Black sold 8,929 shares of Alphatec stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $5.03, for a total transaction of $44,912.87. Following the completion of the sale, the chief financial officer now directly owns 657,770 shares of the company’s stock, valued at approximately $3,308,583.10. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP David Sponsel sold 89,999 shares of Alphatec stock in a transaction on Monday, October 12th. The stock was sold at an average price of $9.47, for a total transaction of $852,290.53. Following the sale, the executive vice president now directly owns 571,840 shares of the company’s stock, valued at $5,415,324.80. The disclosure for this sale can be found here. In the last 90 days, insiders sold 166,659 shares of company stock valued at $1,470,045. Insiders own 34.32% of the company’s stock.

NASDAQ:ATEC opened at $10.11 on Friday. The company has a fifty day simple moving average of $6.82 and a two-hundred day simple moving average of $5.25. The company has a market cap of $654.32 million, a price-to-earnings ratio of -9.02 and a beta of 1.43. The company has a quick ratio of 1.27, a current ratio of 2.24 and a debt-to-equity ratio of 3.51. Alphatec Holdings, Inc. has a 52 week low of $2.19 and a 52 week high of $11.38.

Alphatec (NASDAQ:ATEC) last posted its quarterly earnings results on Thursday, August 6th. The medical technology company reported ($0.25) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.29) by $0.04. The business had revenue of $29.63 million during the quarter, compared to the consensus estimate of $17.26 million. Alphatec had a negative net margin of 56.16% and a negative return on equity of 178.49%. On average, analysts expect that Alphatec Holdings, Inc. will post -1.06 EPS for the current year.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; squadron lateral retractor designed to meet the surgeon's needs and to maximize patient outcomes; LLICO access system, a minimally invasive posterior thoracolumbar access system; Invictus Spinal Fixation System, a comprehensive thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep designed to improve surgical efficiency without compromising accuracy.

Further Reading: Bond

Want to see what other hedge funds are holding ATEC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alphatec Holdings, Inc. (NASDAQ:ATEC).

Institutional Ownership by Quarter for Alphatec (NASDAQ:ATEC)

Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.